1 Introduction
==============

Computational approaches have been developed to predict drug--target interactions (DTIs) ([@btaa451-B14]). Computational-based approaches often predicted DTIs from chemical similarities ([@btaa451-B5]; [@btaa451-B11], [@btaa451-B14]; [@btaa451-B22]; [@btaa451-B25]; [@btaa451-B31]; [@btaa451-B44]; [@btaa451-B47], [@btaa451-B48]; [@btaa451-B54]) and genomic profiles ([@btaa451-B15]; [@btaa451-B16]; [@btaa451-B18]; [@btaa451-B37]; [@btaa451-B42]; [@btaa451-B46]; [@btaa451-B55]). Phenome data were clinically observed from the human, therefore, can offer unique opportunities for novel DTI identification. Drug phenome-based approaches using drug--side effects (SEs) have demonstrated high potential in identifying novel DTIs ([@btaa451-B7]; [@btaa451-B57]). We have recently developed a novel drug--side effect context-sensitive network (DSE-CSN)-based approach to model the context-specific interactions amongst drugs and their associated SEs ([@btaa451-B57]). We demonstrated that the DSE-CSN-based approach had significantly higher performance in DTI prediction as compared to the traditional drug phenome network-based approach. In this study, we propose a significantly improved drug-target prediction approach (TargetPredict) by incorporating a large amount of human phenotype data that we extracted from tens of millions of research articles, patient health data and other free-text documents ([@btaa451-B50]; [@btaa451-B56]).

TargetPredict incorporated 855 904 phenotypic and genetic relationships among 1430 drugs, 4251 SEs, 1059 diseases and 17 860 genes ([Fig. 1](#btaa451-F1){ref-type="fig"}), including a disease comorbidity network (DCN) constructed from the 6 480 372 patient reports in FDA Adverse Event Reporting System (FAERS) ([@btaa451-B56]), and TreatKB, a comprehensive drug--disease treatment knowledge source constructed using natural language processing from 21 million published biomedical research articles ([@btaa451-B47]). The complex relationships were modeled simultaneously using our CSN-based model. The CSN-based model has been validated in predicting DTIs, disease-associated genes and disease-related food metabolites ([@btaa451-B9], [@btaa451-B10]; [@btaa451-B57]). Our previous study showed that the CSN-based model, which preserves the semantic drug--SE relationships, showed higher performance compared to traditional similarity score-based approach in DTI predictions ([@btaa451-B57]).
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We used Alzheimer's disease (AD) as an example to demonstrate that the predicted DTIs have the potential to guide drug discovery. AD is one of the leading causes of dementia in the elderly population, affecting over 5.8 million people in the United States ([@btaa451-B2]). Currently, there exists no cure for AD. The FDA-approved medications, such as cholinesterase inhibitors, can only stabilize the AD's symptoms for a limited time ([@btaa451-B27]). Therefore, there is an urgent need to discover novel drug therapies for AD. We interrogated DTI predictions with known AD genetics to identify repositioned drug candidates. If a drug *d* is predicted to have a new off-target gene *g*, which is known to be involved in AD, we then tested if patients taking drug *d* has lower risk of AD. We performed retrospective case--control studies using patients' electronic health records (EHRs). Currently, we have access to de-identified and population-level EHRs of over 72 million unique patients (20% of the US population from 360 hospitals and 317 000 providers across all 50 states). The EHRs can be accessed from IBM Watson Health Explorys database using Explorys Cohort Discovery ([@btaa451-B28]). Recent studies showed that with unique EHRs and built-in informatics tools, knowledge-driven hypotheses can be evaluated among diverse real-world patient populations with minimum efforts ([@btaa451-B21]; [@btaa451-B30]; [@btaa451-B41]). Our most recent study using this aggregated patients' EHRs from Explorys showed that tumor necrosis factors (TNF) blocking agents (etanercept, adalimumab and infliximab) are significantly associated with reduced risk of AD and dementia in patients with systemic inflammatory diseases ([@btaa451-B58]).

In summary, this study significantly improves our previous phenome-driven DTI prediction algorithm and extends it for drug discovery by (i) integrating additional human phenotypic data mined from public literature, patient health data and other free-text documents; (ii) identifying candidate drugs by interrogating DTI prediction with known disease genetics and (iii) corroborating top candidate drugs using large-scale patients' EHRs.

2 Materials and methods
=======================

[Figure 2](#btaa451-F2){ref-type="fig"} shows the outline of our experiments: (i) we constructed TargetPredict system that consists of 855 904 edges, 1430 drug nodes, 4251 SE nodes, 1059 disease nodes and 17 860 gene nodes; (ii) we predicted DTIs using a standard network-based ranking algorithm and evaluated the prediction ability in *de novo* cross-validation setting using known drug targets and (iii) we identified repositioned candidate drugs by interrogating predicted drug targets with known AD genetics, and evaluated the clinical efficiency of top candidates using EHRs of over 72 million patients.

![Outline of the experiments](btaa451f2){#btaa451-F2}

2.1 Construction of TargetPredict
---------------------------------

### 2.1.1 Context-sensitive phenotypic drug network (DSE-CSN)

We constructed a drug--side effect context-sensitive network (DSE-CSN) as in our previous study ([@btaa451-B57]). The drug--SE pairs were downloaded from Side Effect Resource (SIDER) ([@btaa451-B32]). DSE-CSN consists of 1430 drug nodes, 4251 SE nodes and 145 321 edges between drugs and SEs. Drug and SE terms were mapped their UMLS Concept Unique Identifiers (CUIs) using [@btaa451-B39] V2 release) ([@btaa451-B39]). A drug name or an SE term can only be mapped to a unique concept or CUI. Drug nodes on DSE-CSN are not directly connected; instead, they are connected indirectly through shared SEs.

### 2.1.2 Disease comorbidity network

DCN was built based on 6 480 372 patient health reports using data mining techniques ([@btaa451-B56]). DCN includes 1059 disease nodes and 12 608 edges. Disease names on DCN have been mapped to the UMLS CUIs using MetaMap (2016 V2 release) ([@btaa451-B56]).

### 2.1.3 Drug--disease treatment knowledge base

We used drug--disease treatment relationships to connect DSE-CSN to DCN. In our previous studies, we constructed TreatKBs, which include 111 862 drug--disease pairs (1336 drugs and 8046 diseases) extracted from records of 4.8 million patients in FAERS ([@btaa451-B51]), 9216 drug--disease pairs (1483 drugs and 1381 diseases) extracted from 44 000 FDA drug labels ([@btaa451-B51]), 34 305 pairs (1560 drugs and 7970 diseases) extracted from 21 million MEDLINE abstracts ([@btaa451-B50]) and 69 724 pairs (1286 drugs and 11 848 diseases) from 180 000 clinical trial studies ([@btaa451-B47]). All the terms in TreatKB have already been mapped to UMLS CUIs. Drug nodes on DSE-CSN are connected to disease nodes on DCN based on the drug--disease associations in TreatKB.

### 2.1.4 Connect phenome networks with a protein--protein interaction network

DSE-CSN and DCN were connected to a protein--protein interaction network (PPIN) through known drug-gene and disease-gene associations. PPIN was constructed using protein--protein interactions from STRING database ([@btaa451-B45]). PPIN consisted of 17 860 gene nodes and 689 674 undirected and unweighted edges. We used a cutoff of 400, which is a middle point for PPI association scores ranging from 100 to 900. We used the combined score from STRING database, which were computed by combining the probabilities from the different information sources (e.g. experiments, pathway knowledge bases, text mining) and corrected for the probability of observing an interaction by random ([@btaa451-B45]). This choice of cutoff value and data resource was based on our previous experience in using PPIN in both disease genetics prediction and drug discovery. We found that a too low cutoff could introduced lots of noises, and a too-high cutoff could remove some true signals. The reason for using combined data resources is that these data resources are largely complementary. Drug nodes on DSE-CSN were connected to genes on PPIN using 4142 DTIs from the DrugBank database ([@btaa451-B49]). Disease nodes on DCN were connected to gene nodes on PPIN using 1602 disease-gene associations from Online Mendelian Inheritance in Man (OMIM) ([@btaa451-B24]). We also experimented with connecting SE nodes on DSE-CSN to gene nodes on PPI using disease-gene associations from OMIM.

2.2 Predict potential DTIs from TargetPredict
---------------------------------------------

The input to TargetPredict is a drug and output is a ranked list of genes. We applied the standard random walker with restart network ranking algorithm ([@btaa451-B34]), which we previously applied this algorithm to predict disease genes ([@btaa451-B8]; [@btaa451-B13]), drug targets ([@btaa451-B57]) and repositioned drug candidates ([@btaa451-B52], [@btaa451-B53]). Given an input drug as the seed, the algorithm estimated the probability scores of each gene being reached from the seed. The probability vector at each step is represented by $$\mathbf{p}_{\mathbf{t} + 1} = (1 - \alpha)\mathbf{T}^{\top}\mathbf{p}_{\mathbf{t}} + \alpha\mathbf{p}_{0}$$in which $\mathbf{p}_{0}$ denotes the initial score vector, $\mathbf{p}_{\mathbf{t}}$ denotes the score vector of the *t*-th step and *α* denotes the probability of restarting from the seed node. The algorithm stopped until the difference between the two steps ($\mathbf{L}_{1}$ norm) fall below $10^{- 8}$.

We used *G*, *D* and *P* to represent the heterogeneous network consisting of PPIN, DSE-CSN and DCN. **T** denotes the transition matrix of the entire network, which includes three intra-network transition matrices on the diagonal and six inter-network transition matrices on the off-diagonal: $$\mathbf{T} = \begin{bmatrix}
\mathbf{T}_{GG} & \mathbf{T}_{GD} & \mathbf{T}_{GP} \\
\mathbf{T}_{DG} & \mathbf{T}_{DD} & \mathbf{T}_{DP} \\
\mathbf{T}_{PG} & \mathbf{T}_{PD} & \mathbf{T}_{PP} \\
\end{bmatrix}.$$$\mathbf{A}_{xy}$$(\mathbf{x},\mathbf{y} \in \left\{ G,D,P \right\})$ represents the corresponding adjacency matrices. We regulated the movements of the random walker between any two networks among DSE-CSN, DCN and PPIN with the jumping probability *λ~xy~* $(\mathbf{x},\mathbf{y} \in \left\{ G,D,P \right\})$. For example, if the walker stands on a node on DSE-CSN, which is connected with both DCN and PPIN, it has the option to move to DCN with the probability of *λ~DP~*, move to PPIN with the probability of *λ~DG~* or stay within DSE-CSN with the probability of $1 - \lambda_{DP} - \lambda_{DG}$.

The intra-network transition matrices on the diagonal were calculated in (3), which normalized the intra-adjacency matrix of a network $\mathbf{x}$, and weighted the matrix with the probability of stay within the network: $${(\mathbf{T}_{xx})}_{ij} = \left( 1 - \sum\limits_{y}.I_{y}\lambda_{xy} \right){(\mathbf{A}_{xx})}_{ij}/\sum\limits_{j}{(\mathbf{A}_{xx})}_{ij}.$$

The inter-network transition matrices on the off-diagonal were calculated in (4), which normalized the inter adjacency matrix of a bipartite network $\mathbf{A}_{xy}$ and weighted the matrix with the probability of moving between the network **x** and **y**: $${(\mathbf{T}_{xy})}_{ij} = \begin{cases}
{\lambda_{xy}{(\mathbf{A}_{xy})}_{ij}/\sum\limits_{j}{(\mathbf{A}_{xy})}_{ij},} & {\sum\limits_{j}{(\mathbf{A}_{xy})}_{ij} \neq 0} \\
{0,} & \text{otherwise} \\
\end{cases}.$$

2.3 Investigate the effects of each knowledge base and different configurations of TargetPredict on DTI predictions
-------------------------------------------------------------------------------------------------------------------

We investigated the effects of each knowledge base and different configurations TargetPredicted. We first connected DSE-CSN to DCN through randomly generated drug--disease treatment associations. To generate such random connections, we kept all the drug nodes and disease nodes unchanged but diseases are randomly connected to each drug. We also replaced DCN with a randomized DCN. To generate such a random network, we kept all diseases nodes and total number of edges unchanged but diseases are randomly connected with each other. We next built four TargetPredict systems to investigate how different configurations of connecting DSE-CSN with DCN and PPIN affect the overall performance of DTI prediction. The first TargetPredict system used drug--disease treatment pairs from FDA labels to connect drug nodes on DSE-CSN to disease nodes on DCN. The second TargetPredict system used drug--disease treatment pairs from FAERS to connect drug nodes on DSE-CSN to disease nodes on DCN. The third TargetPredict linked SE nodes to disease nodes on the first TargetPredict model if they represent the same concept. The fourth TargetPredict added the connections between SE nodes and gene nodes on the first TargetPredict model through known disease-gene associations from the OMIM database.

2.4 Evaluation and comparison
-----------------------------

The major advantage of phenome-driven drug-target prediction approaches is that they can predict novel genetic target for drugs without known targets. Thus, we conducted the *de novo* cross-validation, instead of leave-one-out validation, to evaluate how TargetPredict perform in predicting novel drug targets. We tested all of the 910 drugs with known DTIs on DSE-CSN. For each of the 910 drugs, we removed all its known connections to target genes and evaluated if TargetPredict could predict the removed links back and ranked them highly. We also compared TargetPredict to our previous DSE-CSN-based DTI prediction system ([@btaa451-B57]) in the *de novo* cross-validation setting.

We plotted the receiver operating characteristic (ROC) curve to evaluate the performance of TargetPredict. We used 11-point interpolate precision--recall (PR) curves to compare the prediction performance among different systems. For highly skewed data, which is true for any DTI prediction task, PR curves are more accurate than ROC curves in comparing different prediction algorithms ([@btaa451-B19]; [@btaa451-B20]). The overall performance was measured by average precision (MAP) (approximates the area under the curve) of PR curve ([@btaa451-B38]).

The selection of parameters may influence the overall performance of network-based ranking algorithms, including the probability of restart from the seed node *α* and the transition probability among sub-networks. For example, *λ~DG~* between DSE-CSN and PPIN. TargetPredict and DSE-CSN-based prediction system shared DSE-CSN and PPIN. To assure fair comparison, we regulated the common parameters between TargetPredict and DSE-CSN-based system (*α*, *λ~GD~* and *λ~DG~*) in the *de novo* cross-validation. We first fixed other parameters and changed *α* from 0.1 to 0.9. Then we fixed other parameters and changed *λ~DG~* from 0.1 to 0.7. Next, we fixed other parameters and changed *λ~GD~* from 0.1 to 0.7. [Figure 3](#btaa451-F3){ref-type="fig"} indicates that the DSE-CSN-based system achieved the optimal performance when *λ~DG~* was set to 0.3, *λ~GD~* to 0.7 and *α* to 0.9. TargetPredict outperformed DSE-CSN's optimal performance when *α* is greater than 0.3, *λ~DG~* falls between \[0.3, 0.7\] and *λ~GD~* falls between \[0.1, 0.3\]. We set the jumping probability *λ~DP~* as 0.1, *λ~DG~* as 0.3, *λ~PD~* as 0.7, *λ~PG~* as 0.1, *λ~GD~* and *λ~GP~* as 0.3 and *α* as 0.7 for TargetPredict. We used these parameters combination for the subsequent analysis.
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2.5 Large-scale EHRs-based clinical corroboration for AD drug repositioning
---------------------------------------------------------------------------

We used AD as an example to demonstrate that our predicted DTIs have the potential to guide drug discovery. We downloaded 679 AD-associated genes from the AlzGene database ([@btaa451-B4]). For each drug, we set the drug as the seed node and predicted its novel targets using TargetPredict. TargetPredict outputs the probability scores of each gene of being reached from the drug seed. We sum up the probability scores for AD-associated genes for each drug and prioritize all the 1430 drugs based on the sum of scores.

### 2.5.1 Database description

We performed large-scale retrospective case--control studies to demonstrate that drugs identified using TargetPredict has the potential to benefit real-word AD patients. The de-identified EHR data for patients with age over 65 years old are used as AD is a disease prevalent in elderly population. Explorys collected patient information including disease diagnoses history, drug use history, laboratory test results, demographics, procedures and finding from multiple health information systems. The data were normalized using standard biomedical terminologies from UMLS ([@btaa451-B6]). Specifically, the disease names were normalized with Systematized Nomenclature of Medicine-Clinical Terms, a health terminology standard in US Federal Government systems for the efficient exchange of interoperable EHRs ([@btaa451-B43]). Individual drug names were normalized with RxNorm, a standard nomenclature for clinical drugs developed by the US National Library of Medicine ([@btaa451-B40]). Laboratory tests were normalized by logical observation identifier names and codes ([@btaa451-B36]). At the time of the study, the Explorys Cohort Discovery platform contained over 72 million unique patients among which over 17 million were over 65 years.

### 2.5.2 Study population

We investigated if patients who were prescribed the top 30 drug candidates have lower risks of AD or the border diagnose of dementia. We first identified all patients aged over 65 years. For a candidate drug D1, we extracted patients with a diagnose code of its original treatment disease P1 as the study cohort. The study cohort was further separated as the drug group and no-drug group. The drug group included patients with P1 and prescribed D1. The no-drug group is patients with P1 but with no records of prescribing D1. Considering the possibility of misdiagnosis of AD in the EHR database, we used both AD and the broader diagnosis of dementia (including AD) as the outcomes. Among patients over 65 years, 334 750 of them have a diagnosis code of AD, 883 260 of them have a broader diagnosis of dementia. Similar methods were used to identify patients with other disease diagnosis codes. Patients who prescribed a drug were identified by searching the generic drug names from RxNorm.

### 2.5.3 Statistical analysis

We calculated the risk associations of candidate drugs with AD as we did in our previous study ([@btaa451-B58]). The associations between candidate drugs and risks of AD/dementia were estimated by odds ratios of AD/dementia over drug use groups versus non-drug use groups. Due to the fact that we do not have access to patient-level data, the adjusted odds ratios (AORs), 95% confidence intervals (CIs) and *P*-values were calculated using Cochran--Mantel--Haenszel (CMH) method by controlling for confounding factors including age, gender and race. To compute AOR, we first compute the OR of each of the 24 strata (tabulation of two genders: female and male, two races: Caucasian and non-Caucasian, six age groups: 65--69, 70--74, 75--79, 80--84, 85--89, over 90), then weighted average across all strata. A *P*-value \< 0.05 (two-sided) was considered as statistical significance. Among the top 30 drugs, we excluded drugs that do not have enough prescribers (e.g. rarely used drugs) to performed the CMH analysis (at least one element in the contingency table is \<10 at all strata). Among the top 30 drugs, 10 were excluded for dementia and 14 were excluded for AD.

3 Results
=========

3.1 Performance measure and comparison as measured by ROC curve
---------------------------------------------------------------

TargetPredict achieved a high area under the curve (AUC) of 0.97 ([Fig. 4](#btaa451-F4){ref-type="fig"}). ROC curves, however, did not show a clear advantage of TargetPredict compared to the DSE-CSN-based system. In this study, the number of negative examples (genes not targeted by drugs) greatly surpasses the number of positive examples (known drug targets). The ROC curves usually overestimate the performance for highly skewed datasets ([@btaa451-B19]). Thus, there are two potential reasons for similar ROC curves between TargetPredict and DSE-CSN-based system: (i) the prediction ability of the two models is similar and (ii) the highly skew data obscured the difference of prediction ability between these two models.
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3.2 Performance measure and comparison as measured by PR curves
---------------------------------------------------------------

We then used PR curves to compare TargetPredict with the DSE-CSN-based system. [Figure 5a](#btaa451-F5){ref-type="fig"} shows the performance of TargetPredict, which connects drug nodes to disease nodes using the FDA-approved drug--disease treatment pairs, and compared it to DSE-CNS approach. The PR curves show that the MAP of TargetPredict is 0.28, which is significantly higher than the DSE-CSN-based system (MAP = 0.23, *P*-value \< 0.0001). To investigate the effects of drug--disease treatment relationships on the overall performance, we connected DSE-CSN to DCN through randomly generated drug--disease treatment associations. PR curves in [Figure 5a](#btaa451-F5){ref-type="fig"} show that TargetPredict with random drug--disease connections yielded an MAP of 0.20, which is significantly lower than that using the drug--disease treatment relationships from FDA labels (*P*-value \< 0.0001). These results demonstrated that integrating disease comorbidity with drug--SE information through FDA-approved drug--disease treatment pairs can significantly improve DTI predictions. We also generated a random DCN on which the disease nodes are randomly connected. However, due to the high connection of DCN, we did not observe a significant influence of random DCN.

![The PR curves between TargetPredict and DSE-CSN-based system](btaa451f5){#btaa451-F5}

Drug--disease treatment pairs mined from FAERS are more comprehensive but noisier than those extracted from FDA drug labels. We observed in [Figure 5b](#btaa451-F5){ref-type="fig"} that TargetPredict using drug--disease treatment pairs from FAERS had better performance than DSE-CSN system (MAP: 0.26 versus 0.23, *P*-value \< 0.0001), but lower performance than that using the drug--disease treatment pairs from FDA labels (MAP: 0.28 versus 0.23, *P*-value \< 0.0001). These results demonstrated that connecting DSE-CSN to DCN through highly accurate drug--disease treatment relationships is important for DTI predictions.

We then investigated if connecting SEs to diseases or genes can further improve the performance. [Figure 6a](#btaa451-F6){ref-type="fig"} shows that connecting SEs with disease nodes on TargetPredict using the same UMLS CUIs did not significantly improve the prediction ability. This may be due to the fact that not many SE nodes on DSE-CNS can be mapped to disease nodes on DCN. [Figure 6b](#btaa451-F6){ref-type="fig"} shows that connecting SEs to genes yielded lower performance. This may be caused by the uncertain associations between SEs and genes from existing disease genetics databases as well as the noisy nature of drug--SE associations from SIDER. This suggests that while integrating more data (data quantity) can include more information; DTI prediction would also depend on data accuracy or data quality.
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3.3 TargetPredict has the potential to identify novel drug therapies for AD
---------------------------------------------------------------------------

We used TargetPredict (constructed using drug--disease treatment pairs from FDA labels) to perform target-based drug repositioning toward AD. The top 30 ranked drugs are listed in [Table 1](#btaa451-T1){ref-type="table"}. Among the top 30 drugs, rivastigmine has been approved for the treatment of dementia associated with AD or Parkinson's disease. Donepezil has been approved for palliation of Dementia of the Alzheimer's type. In addition, six of the top-ranked drugs have been tested in clinical trials for treating AD. These results further confirmed the validity of our drug discovery strategy by interrogating genetic drug targets predicted by TargetPredict with known disease genetics.

###### 

Top 30-ranked repositioned drug candidates

  Rank   Drug name          Original indication           Evidence
  ------ ------------------ ------------------------ ------------------
  1      Malathion          Head lice                
  2      Echothiophate      Angle-closure glaucoma   
  3      Rivastigmine       Dementia                  **FDA-approved**
  4      Edrophonium        Muscle relaxants         
  5      Pralidoxime        Nerve agent poisoning    
  6      Pravastatin        Hypercholesterolemia     
  7      Fluvastatin        Hypercholesterolemia     
  8      Neostigmine        Myasthenia gravis        
  9      Rosuvastatin       Hyperlipidemia           
  10     Pyridostigmine     Myasthenia gravis        
  11     Lorcaserin         Obesity                  
  12     Disulfiram         Alcohol dependence       
  13     Gemfibrozil        Hyperlipidemia              NCT02045056
  14     Donepezil          AD                        **FDA-approved**
  15     Bacitracin         Bacterial infections     
  16     Sulfamethoxazole   Bacterial infectious     
  17     Aliskiren          Hypertension             
  18     Anastrozole        Breast cancer            
  19     Physostigmine      Glaucoma                 
  20     Exemestane         Breast cancer            
  21     Letrozole          Breast cancer            
  23     Prednisone         Inflammation                NCT00000178
  24     Testolactone       Breast cancer            
  25     Varenicline        Nicotine dependence         NCT00744978
  26     Pioglitazone       Type 2 diabetes             NCT01931566
  27     Dipivefrin         Glaucoma                 
  28     Liraglutide        Type 2 diabetes             NCT01843075
  29     Abiraterone        Prostate cancer          
  30     Etoricoxi          Osteoarthritis           

*Note*: NCT\*\*: AD drugs from clinical trials. FDA-approved AD drugs are highlighted in bold.

To further test the clinical efficiency of top-ranked drug candidates, we performed retrospective case--control studies using patients' EHRs data. The AORs, 95% CIs and *P*-values were plotted in [Figures 7](#btaa451-F7){ref-type="fig"} and [8](#btaa451-F8){ref-type="fig"}. The vertical line where AOR equals 1 suggests that there is no association between drug use and AD (or dementia). The right to the vertical reference line suggests that the odds of AD/dementia is higher for drug group than for no-drug group, and the left to the vertical reference line suggests that the odds of AD/dementia is lower for the drug than for the no-drug group.

![The effects of top-ranked drugs for AD](btaa451f7){#btaa451-F7}

![The effects of top-ranked drugs for Dementia](btaa451f8){#btaa451-F8}

Among the top drugs studied, [Figure 6](#btaa451-F6){ref-type="fig"} showed the potential clinical efficiency for preventing or treating AD (AOR \< 1.0, *P*-value \< 0.05). For example, liraglutide was previously approved to treat type 2 diabetes. Among senior patients with type 2 diabetes, odds of being diagnosed with AD was 24% lower \[AOR: 0.76; 95% CI (0.70, 0.82), *P*-value \< 0.0001\] among patients prescribed liraglutide compared with those who did not prescribe the drug after controlling age, gender and races ([Fig. 7](#btaa451-F7){ref-type="fig"}). The potential benefit of liraglutide was replicated in patients with a diagnosis code of dementia \[AOR: 0.80; 95% CI (0.77, 0.84), *P*-value \< 0.0001\]. Interestingly, a study showed that liraglutide indeed prevented the loss of brain insulin receptors, an import feature of the AD brain and reversed memory impairment in both mice and non-human primates ([@btaa451-B3]). These results indicate that TargetPredict has potential in identifying novel candidate anti-AD drugs, which have both clinical efficacy evidence gathered from real-world AD patients and interpretable mechanisms of action (e.g. liraglutide ≥ GLP1R ≥ AD).

We also identified that pravastatin and fluvastatin associated with a higher risk of AD and dementia ([Figs 7 and 8](#btaa451-F7){ref-type="fig"}). Previous meta-analysis suggested that statins associated with reduced risk of AD and dementia ([@btaa451-B17]). Fluvastatin and pravastatin belong to a subtype of statins called hydrophilic statins ([@btaa451-B33]). The associations between hydrophilic statin use and risk of AD (or dementia) are inconsistent across different studies. For example, a study using 6992 patients suggested that hydrophilic statins do not significantly associate the risk of AD ([@btaa451-B23]). Some studies showed that hydrophilic statins users have higher risks of AD compared to lipophilic statins users ([@btaa451-B35]). In fact, meta-analysis suggested that the association between hydrophilic statins and risk of AD is relatively weak (Adjusted Relative Risk = 0.619; CI = 0.383--1.000; *P* = 0.050) ([@btaa451-B17]). Previous observation studies tend to have a limited sample size, which could bias the results. The advantage of our study is that we studied the drug outcomes using EHRs of 72 million unique patients including 63 million adults and seniors (20% of US population across 50 states), which overcame many of the limitations from traditional epidemiological studies due to small sample sizes, high sampling errors and high sample selection bias that impeded their generalizability. We believe that our study may provide more robust evidence supporting the risk associations of pravastatin and fluvastatin with AD.

Our top-ranked drugs also included some drugs that do not significantly associated AD. For example, TargetPredict ranked prednisone, a drug used to treat rheumatoid arthritis (RA), on top 23. In our patients' EHRs analysis, among patients diagnosed with RA, prescription of prednisone did not significantly associate with risk of AD diagnosis \[AOR: 1.01; 95% CI (0.97, 1.04); *P*-value = 0.74\]. A clinical trial study also failed to show the benefits of prednisone in cognitive decline in AD patients ([@btaa451-B1]). Since the genetic mechanisms underlying AD are not fully revealed, genes from AlzGene database may not be the true underlying genes ([@btaa451-B4]). Therefore, drugs target genes from AlzGene may not truly target the genetic mechanisms of AD. One of our naturally future direction is to develop drug repositioning methods that allows us to predict diseases with unknown mechanisms.

4 Discussion
============

In this study, we developed an integrated computational drug discovery approach by seamlessly combining DTI prediction and clinical corroboration. We demonstrated that TargetPredict performed better than the state-of-the-art phenome-driven system. We investigated the potential of TargetPredict in novel drug repositioning for AD by interrogating predicted drug targets with AD genetics. We evaluated the clinical efficiency of top repositioned drug candidates using EHRs of over 72 million patients.

Our study can be further improved. First, we evaluated TargetPredict for 910 drugs in a *de novo* validation scheme using known drug-target associations. The *de novo* validation is more stringent than leave-one-out validation in evaluating the *de novo* prediction power of an algorithm. In addition, our EHR-based corroboration in some degree tested TargetPredict's potential in identifying novel drug targets. However, to further evaluate how this system performs in identifying truly novel drug off-targets will need experimental testing.

Second, EHRs from Explorys Cohort Discovery are de-identified population-level data. Patient-level information like exact age at diagnosis, duration of treatment or years of follow up are not accessible. In this study, we were not able to constrain the time windows between disease diagnosis and drug use in this study. We will need further evaluate the top candidate drugs in cohort studies using patient-level data.

Third, the TargetPredict model also has limitations. For example, the DCN was constructed using the disease characteristics of patients from FAERSs. The medications and reported drug-related adverse events were not used in constructing the DCN. The disease commodity network constructed from FAERS can be further improved by information from other data resources, including EHRs, biomedical literature, among others. For example, [@btaa451-B26] constructed a DCN using 3 years of Medicare claims of 30 million Americans. This network captures disease comorbidity relationships in specific race and gender groups. The limitation is that the data only included patients 65 years or older ([@btaa451-B26]). In another study, [@btaa451-B29] identified the temporal disease comorbidities from 6.2 million patients' data in Denmark. The data sources are less population biased and capture the temporal disease progression. However, the disease comorbidity was identified using relative risks, which may lead to an intrinsic bias toward rare diseases ([@btaa451-B12]). In the future, we would like to develop methods to integrate disease phenotypic information extracted from different sources to compensate for the limitations of each single knowledge base. For example, for rare diseases, we would set more weights from comorbidity relationships extracted from FAERS. Another future direction is that we will experiment with adding disease-gene associations from Genome-Wide Association Studies (GWAS) data to the entire network. Currently, we used disease-gene associations from OMIM instead of GWAS to connect disease nodes on DCN to PPIN because that disease-gene associations from OMIM are much stronger (often are causal) than those from GWAS and there are more diseases in OMIM database as compared to GWAS. We will investigate methods to incorporate GWAS data by experimenting with different weighting schemes. For example, we can make the random walker less likely to jump to the GWAS-based disease-gene network as compared to the OMIM-based network. We will also investigate methods or further data resources to weight disease-gene association strengths from GWAS data, which may provide more robust ways to incorporate GWAS data.

Last but not least, we demonstrated the potential of TargetPredict for AD drug discovery by seamlessly integrating our drug-target discovery with patients' EHRs-based clinical corroborations. TargetPredict platform included 1430 approved drugs and the Explorys database includes patients with the diagnosis of tens of thousands for diseases. Currently, we are applying this strategy for drug discovery for other diseases, including schizophrenia, depression, cancers and substance addiction. However, how our system performs for a specific disease will depend on how much disease-relevant data and knowledge included in TargetPredict as well as the number of patients with the disease included in the Explorys database.
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